Non-melanoma skin cancer as a possible adverse event due to anti-interleukin-6 treatment

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden

(2016) Pauline Raaschou et al.   BMJ-British Medical Journal

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden

(2016) Pauline Raaschou et al.   BMJ-British Medical Journal

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer

(2015) C. S. Milagre et al.   CANCER RESEARCH

The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target

(2013) Daniel C Gaffney et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?

(2012) A. Finet et al.   CLINICAL RHEUMATOLOGY

Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

(2012) Maria A. Lopez-Olivo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation

(2012) Sylvie Euvrard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma

(2009) S. Shinriki et al.   CLINICAL CANCER RESEARCH